GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biological Inc (SZSE:301047) » Definitions » Piotroski F-Score

Sino Biological (SZSE:301047) Piotroski F-Score : 4 (As of Apr. 23, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Sino Biological Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sino Biological has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sino Biological's Piotroski F-Score or its related term are showing as below:

SZSE:301047' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 4

During the past 8 years, the highest Piotroski F-Score of Sino Biological was 5. The lowest was 2. And the median was 4.


Sino Biological Piotroski F-Score Historical Data

The historical data trend for Sino Biological's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biological Piotroski F-Score Chart

Sino Biological Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial N/A 5.00 2.00 4.00 4.00

Sino Biological Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 5.00 4.00

Competitive Comparison of Sino Biological's Piotroski F-Score

For the Biotechnology subindustry, Sino Biological's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biological's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biological's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sino Biological's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 43.761 + 27.179 + 28.375 + 22.612 = ¥121.9 Mil.
Cash Flow from Operations was 17.137 + 22.144 + 35.341 + 39.112 = ¥113.7 Mil.
Revenue was 152.349 + 153.312 + 159.289 + 148.722 = ¥613.7 Mil.
Gross Profit was 117.928 + 106.751 + 121.323 + 103.754 = ¥449.8 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(6600.678 + 6517.113 + 6301.037 + 6030.344 + 6054.709) / 5 = ¥6300.7762 Mil.
Total Assets at the begining of this year (Dec23) was ¥6,600.7 Mil.
Long-Term Debt & Capital Lease Obligation was ¥44.9 Mil.
Total Current Assets was ¥4,207.6 Mil.
Total Current Liabilities was ¥197.5 Mil.
Net Income was 83.695 + 51.964 + 69.538 + 54.935 = ¥260.1 Mil.

Revenue was 157.086 + 135.292 + 183.684 + 170.327 = ¥646.4 Mil.
Gross Profit was 135.026 + 97.6 + 154.248 + 143.538 = ¥530.4 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(6580.211 + 6645.508 + 6429.252 + 6502.124 + 6600.678) / 5 = ¥6551.5546 Mil.
Total Assets at the begining of last year (Dec22) was ¥6,580.2 Mil.
Long-Term Debt & Capital Lease Obligation was ¥61.7 Mil.
Total Current Assets was ¥5,069.0 Mil.
Total Current Liabilities was ¥136.4 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sino Biological's current Net Income (TTM) was 121.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sino Biological's current Cash Flow from Operations (TTM) was 113.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=121.927/6600.678
=0.01847189

ROA (Last Year)=Net Income/Total Assets (Dec22)
=260.132/6580.211
=0.03953247

Sino Biological's return on assets of this year was 0.01847189. Sino Biological's return on assets of last year was 0.03953247. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sino Biological's current Net Income (TTM) was 121.9. Sino Biological's current Cash Flow from Operations (TTM) was 113.7. ==> 113.7 <= 121.9 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=44.898/6300.7762
=0.00712579

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=61.69/6551.5546
=0.00941609

Sino Biological's gearing of this year was 0.00712579. Sino Biological's gearing of last year was 0.00941609. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=4207.573/197.521
=21.30190208

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=5069.036/136.378
=37.16901553

Sino Biological's current ratio of this year was 21.30190208. Sino Biological's current ratio of last year was 37.16901553. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sino Biological's number of shares in issue this year was 0. Sino Biological's number of shares in issue last year was 0. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=449.756/613.672
=0.73289314

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=530.412/646.389
=0.82057708

Sino Biological's gross margin of this year was 0.73289314. Sino Biological's gross margin of last year was 0.82057708. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=613.672/6600.678
=0.09297106

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=646.389/6580.211
=0.09823226

Sino Biological's asset turnover of this year was 0.09297106. Sino Biological's asset turnover of last year was 0.09823226. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sino Biological has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Sino Biological  (SZSE:301047) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sino Biological Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sino Biological's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biological Business Description

Traded in Other Exchanges
N/A
Address
No. 18 Kechuang 10th Street, Room 306, Building 9, Beijing Economic and Technological Development Zon, Beijing, CHN, 100176
Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.

Sino Biological Headlines

No Headlines